Androgen receptor or estrogen receptor-β blockade alters DHEA-, DHT-, and E2-induced proliferation and PSA production in human prostate cancer cells

Prostate

Volumn 67, Issue 11, 2007, Pages 1152-1162

  Arnold, Julia T ^a,c   Liu, Xunxian ^a   Allen, Jeffrey D ^a   Le, Hanh ^a   McFann, Kimberly K ^b   Blackman, Marc R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LCI   (United States)

Author keywords

AR; Casodex; DHEA; DHT; E2; ER ; ICI 182,780; PSA

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; ESTRADIOL; ESTROGEN RECEPTOR BETA; FULVESTRANT; MESSENGER RNA; METRIBOLONE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN LNCAP; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION;

ANDROGEN ANTAGONISTS; ANILIDES; CELL DIVISION; CELL LINE, TUMOR; DEHYDROEPIANDROSTERONE; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; GENE EXPRESSION; HUMANS; MALE; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; RNA, SMALL INTERFERING; TESTOSTERONE; TOSYL COMPOUNDS;

EID: 34547700033     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20585     Document Type: Article

References (39)

1. Alesci S, Manoli I, Blackman MR. Dehydrodepiandrosterone (DHEA). In: Coates P, Blackman MR, Cragg G, Levine M, Moss J, White J, editors. Encyclopedia of dietary supplements, 1st ed. New York, NY: Marcel Dekker, Inc.; 2005:167-176.
2. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005; 288(3):E573-E584.
3. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41(3-8):665-669.
4. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002; 87(1):176-181.
5. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60(12):3175-3182.
6. Zhu YS, Cai LQ, Huang Y, Fish J, Wang L, Zhang ZK, Imperato-McGinley JL. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens. J Androl 2005;26:4500-4508; discussion 509-510.
7. Martin C, Ross M, Chapman KE, Andrew R, Bollina P, Seckl JR, Habib FK. CYP7B generates a selective estrogen receptor beta agonist in human prostate. J Clin Endocrinol Metab 2004;89(6): 2928-2935.
8. Le H, Arnold JT, McFann KK, Blackman MR. Dihydrotestosterone, Testosterone, but not DHEA or Estradiol, differentially modulate IGF-I, IGFBP-2 and IGFBP-3 Gene and protein expression in primary cultures of human prostatic stromal cells. Am J Physiol Endocrinol Metab 2005;290(5):E952-E960.
9. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Curr Biol 2005;15(22):1989-1997.
10. Ho SM. Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91(3):491-503.
11. Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, Birch L. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998;139 (3):874-883.
12. Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala A, Kaija H, Isomaa V, Vihko P. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):281-286.
13. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer 2003;10(2):187-191.
14. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
15. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 2002;9(1):61-73.
16. Klein H, Molwitz T, Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: Characterization and quantification of the enzyme in epithelium and stroma. J Steroid Biochem 1989;33(2):195-200.
17. Widstrom RL, Dillon JS. Is there a receptor for dehydroepian-drosterone or dehydroepiandrosterone sulfate? Semin Reprod Med 2004;22(4):289-298.
18. Labrie F. Inrracrinology. Mol Cell Endocrinol 1991;78(3):C113-C118.
19. Geller J, Albert JD. Adrenal androgen blockade in relapsed prostate cancer. Eur J Cancer Clin Oncol 1985;21(10):1127-1131.
20. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP, Reszka AA. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology 2005;146(11):4568-4576.
21. Arnold JT, Blackman MR. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer? Endocrinology 2005;146(11):4565-4567.
22. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985-1992.
23. Singh H, Dang TD, Ayala GE, Rowley DR. Transforming growth factor-beta1 induced myofibroblasts regulate LNCaP cell death. J Urol 2004;172 (6 Pt 1):2421-2425.
24. Simard J, Gingras S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol Cell Endocrinol 2001;171(1-2):25-40.
25. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3(4):402-408.
26. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999;162(6):2192-2199.
27. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 2006;5(6):1539-1549.
28. Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, Pezzi V, Briand PA, Picard D, Ando S. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004;32(3):777-791.
29. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95(26):15677- 15682.
30. Peekhaus NT, Chang T, Hayes EC, Wilkinson HA, Mitra SW, Schaeffer JM, Rohrer SP. Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7. J Mol Endocrinol 2004;32(3): 987-995.
31. Van Den Bemd GJ, Kuiper GG, Pols HA, Van Leeuwen JP. Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 1999;261(1):1-5.
32. Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int 2000;65(2):73-79.
33. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63(1):149-153.
34. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65(21):9611-9616.
35. Sun J, Baudry J, Katzenellenbogen JA, Katzenellenbogen BS. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Mol Endocrinol 2003;17(2):247-258.
36. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ER beta in the uterus. Endocrinology 2003;144(7):3159-3166.
37. Biberger C, von Angerer E. 2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity. J Steroid Biochem Mol Biol 1996;58(1):31-43.
38. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19(20):5406-5417.
39. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000;167(1-2):139-150.